Cantor Fitzgerald Weighs in on Editas Medicine FY2025 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Editas Medicine in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings per share of ($2.10) for the year. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.73) per share.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.75) EPS for the quarter, meeting analysts’ consensus estimates of ($0.75). The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $3.93 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The company’s quarterly revenue was down 98.9% compared to the same quarter last year. During the same period last year, the company earned ($0.55) earnings per share.

EDIT has been the subject of several other reports. Chardan Capital reiterated a “neutral” rating on shares of Editas Medicine in a report on Friday, December 13th. Evercore ISI lowered their target price on Editas Medicine from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, December 16th. Royal Bank of Canada cut their price target on shares of Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating for the company in a report on Friday, December 13th. Robert W. Baird lowered their price objective on shares of Editas Medicine from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Friday, December 13th. Finally, Stifel Nicolaus lowered shares of Editas Medicine from a “buy” rating to a “hold” rating and cut their target price for the company from $11.00 to $3.00 in a research note on Friday, December 13th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.00.

Editas Medicine Stock Up 10.7 %

Shares of EDIT opened at $1.34 on Wednesday. Editas Medicine has a 52-week low of $1.12 and a 52-week high of $11.58. The firm has a market capitalization of $110.62 million, a PE ratio of -0.52 and a beta of 1.95. The firm has a 50-day moving average price of $1.73 and a 200 day moving average price of $3.17.

Hedge Funds Weigh In On Editas Medicine

A number of large investors have recently made changes to their positions in EDIT. Rhumbline Advisers grew its position in Editas Medicine by 2.9% during the second quarter. Rhumbline Advisers now owns 137,986 shares of the company’s stock valued at $644,000 after purchasing an additional 3,862 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Editas Medicine by 13.6% during the 2nd quarter. American Century Companies Inc. now owns 126,240 shares of the company’s stock valued at $590,000 after buying an additional 15,088 shares during the period. Hsbc Holdings PLC grew its holdings in shares of Editas Medicine by 148.1% during the 2nd quarter. Hsbc Holdings PLC now owns 104,794 shares of the company’s stock valued at $488,000 after acquiring an additional 62,561 shares in the last quarter. Caxton Associates LP acquired a new position in shares of Editas Medicine in the second quarter worth $600,000. Finally, AQR Capital Management LLC raised its holdings in shares of Editas Medicine by 117.2% during the second quarter. AQR Capital Management LLC now owns 45,890 shares of the company’s stock worth $214,000 after acquiring an additional 24,758 shares in the last quarter. Institutional investors and hedge funds own 71.90% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.